December 2010

The ravages of lung cancer due to cigarette smoking are all too familiar to oncology healthcare providers.

Useful Online Resources and Clinical Trials for Non-Small Cell Lung Cancer

Useful Online Resources and Clinical Trials for Acute Myelogenous Leukemia

Useful Online Resources and Clinical Trials for Ovarian Cancer

Useful Online Resources and Clinical Trials for Renal Cell Carcinoma

Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia

A new scoring system has been developed that is designed to predict the risk of recurrent venous thromboembolism (VTE) in a patient with cancer.

An investigational pan-BCR-ABL inhibitor designed to inhibit the entire spectrum of mutations responsible for resistance to drugs such as imatinib (Gleevec) and its cousins nilotinib (Tasigna) and dasatinib (Sprycel) appears to fulfill its promise.

In patients with early unfavorable Hodgkin lymphoma, an escalated BEACOPP regimen was superior to standard treatment at improving tumor control, according to final data from the German Hodgkin Study Group HD14 trial.

A North Carolina State University study takes the US media to task for writing articles on cancer that use ambiguous terms and increase patients' uncertainty

The University of Glasgow will begin offering medical and scientific research findings, including cancer-related discoveries, to businesses and entrepreneurs free of charge

The FDA has awarded a $600,000 grant for a phase I clinical trial of a genetically reprogrammed herpes simplex virus in young cancer patients with relapsed non-central nervous system (CNS) solid tumors such as sarcomas and neuroblastomas.

Lung Cancer Screening Test Raises Hopes and Sets Stage for Discussion of Guidelines The Lung Cancer Alliance is pressing for a full discussion about the guidance on whether people at high risk for lung cancer should undergo screening

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

Healthy People 2020 Puts Cancer Prevention on Agenda Healthy People 2020, the federal government's recently released 10-year program to improve the health of Americans during the coming decade

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.

California Researchers Receive Highest Honors From ASTRO Two prominent California-based radiation oncologists are the recipients of Gold Medal awards from the American Society for Radiation Oncology (ASTRO) this year.

Denosumab, a monoclonal antibody that has proved effective in preventing bone fractures and bone pain for patients whose cancer has metastasized and damaged the bone, won approval from the FDA after a 6-month priority review.

There are multiple factors to consider when deciding whether to practice in an country or a city setting

The genuine revolution in our understanding of the genetic basis of malignant disease has led to a corresponding interest in defining the risk of developing a particular disease for both individuals and specific populations.

Useful Online Resources and Clinical Trials for Colon Cancer

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a phase II study of younger patients with relapsed or refractory Hodgkin lymphoma (HL) who had no other treatment options

It was 40 years ago in January that Richard Nixon, still grappling with the Vietnam War and not yet overwhelmed by scandal, stood before Congress to deliver the State of the Union address and declared a bold new goal for the nation.

When Patricia Hardenbergh, MD, left the academic environment of Duke University Medical Center in North Carolina to become director of radiation oncology in a mountain town in Colorado about 10 years ago, it was more than simply an 1800-mile change of scenery.